Letter to the Editor
The incremental benefits of implementing effective cervical cancer screening
Salvatore Vaccarella,
Corresponding Author
Salvatore Vaccarella
International Agency for Research on Cancer, 69372 Lyon Cedex 08 France
Correspondence to: Salvatore Vaccarella, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France, Tel.: +[33-(0)4-72-73-80-97], Fax: +[33-(0)4-72-73-83-45], E-mail:
[email protected]Search for more papers by this author Silvia Franceschi,
Silvia Franceschi
International Agency for Research on Cancer, 69372 Lyon Cedex 08 France
Search for more papers by this author Freddie Bray,
Freddie Bray
International Agency for Research on Cancer, 69372 Lyon Cedex 08 France
Search for more papers by this author
Salvatore Vaccarella,
Corresponding Author
Salvatore Vaccarella
International Agency for Research on Cancer, 69372 Lyon Cedex 08 France
Correspondence to: Salvatore Vaccarella, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France, Tel.: +[33-(0)4-72-73-80-97], Fax: +[33-(0)4-72-73-83-45], E-mail:
[email protected]Search for more papers by this author Silvia Franceschi,
Silvia Franceschi
International Agency for Research on Cancer, 69372 Lyon Cedex 08 France
Search for more papers by this author Freddie Bray,
Freddie Bray
International Agency for Research on Cancer, 69372 Lyon Cedex 08 France
Search for more papers by this author
First published: 23 July 2015
No abstract is available for this article.
References
- 1
Lönnberg S,
Hansen BT,
Haldorsen T, et al. Cervical cancer prevented by screening: long-term incidence trends by morphology in Norway. Int J Cancer 2015; 137: 1758–64. doi:10.1002/ijc.29541.
- 2 International Collaboration of Epidemiological Studies of Cervical Cancer. Comparison of risk factors for invasive squamous cell carcinoma and adenocarcinoma of the cervix: collaborative reanalysis of individual data on 8,097 women with squamous cell carcinoma and 1,374 women with adenocarcinoma from 12 epidemiological studies. Int J Cancer 2007; 120: 885–91.
- 3
Vaccarella S,
Franceschi S,
Engholm G, et al. 50 years of screening in the Nordic countries: quantifying the effects on cervical cancer incidence. Br J Cancer 2014; 111: 965–9.
- 4
Vaccarella S,
Lortet-Tieulent J,
Plummer M, et al. Worldwide trends in cervical cancer incidence: impact of screening against changes in disease risk factors. Eur J Cancer 2013; 49: 3262–73.
- 5
Harper DM,
Nieminen P,
Paavonen J, et al. Cervical cancer incidence can increase despite HPV vaccination. Lancet Infect Dis 2010; 10: 594–5. S1473-3099(10)70182-1 [pii];10.1016/S1473-3099(10)70182-1 [doi].
- 6
Bray F,
Lortet-Tieulent J,
Znaor A, et al. Patterns and trends in human papillomavirus-related diseases in Central and Eastern Europe and Central Asia. Vaccine 2013; 31 (Suppl 7): H32–H45. S0264-410X(13)00476-3 [pii];10.1016/j.vaccine.2013.02.071 [doi].
- 7
Dillner J,
Rebolj M,
Birembaut P, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 2008; 337: a1754.
